IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Jump Financial LLC

Jump Financial LLC lessened its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 78.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,241 shares of the medical research company's stock after selling 26,626 shares during the quarter. Jump Financial LLC's holdings in IQVIA were worth $1,423,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in IQV. Synergy Asset Management LLC purchased a new position in shares of IQVIA during the 4th quarter worth $33,000. Lee Danner & Bass Inc. purchased a new stake in shares of IQVIA in the 4th quarter valued at approximately $44,000. Zions Bancorporation N.A. increased its holdings in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after buying an additional 85 shares during the last quarter. Versant Capital Management Inc lifted its holdings in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after acquiring an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in IQVIA in the fourth quarter worth approximately $60,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. UBS Group lowered their price target on IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a report on Friday, February 7th. StockNews.com downgraded shares of IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Stifel Nicolaus lowered their price objective on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Citigroup decreased their price target on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Finally, Barclays reaffirmed an "equal weight" rating and issued a $170.00 price objective (down from $235.00) on shares of IQVIA in a research note on Thursday, April 10th. Seven research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of "Moderate Buy" and an average target price of $237.62.

IQVIA Stock Performance

Shares of NYSE:IQV traded down $0.63 during midday trading on Friday, hitting $150.05. The stock had a trading volume of 535,737 shares, compared to its average volume of 1,686,057. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market capitalization of $26.46 billion, a PE ratio of 20.01, a P/E/G ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 1 year low of $135.97 and a 1 year high of $252.88. The stock has a 50 day moving average price of $172.46 and a two-hundred day moving average price of $194.57.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.